159 related articles for article (PubMed ID: 37856034)
1. Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry.
Kubo S; Miyazaki Y; Todoroki Y; Nagayasu A; Kanda R; Aritomi T; Matsunaga S; Ueno M; Miyagawa I; Sonomoto K; Hanami K; Nakayamada S; Tanaka Y
Rheumatol Ther; 2023 Dec; 10(6):1705-1723. PubMed ID: 37856034
[TBL] [Abstract][Full Text] [Related]
2. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Etani Y; Maeda Y; Okita Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Hara R; Nagai K; Hiramatsu Y; Son Y; Amuro H; Fujii T; Okano T; Ueda Y; Katayama M; Okano T; Tachibana S; Hayashi S; Kumanogoh A; Okada S; Nakata K
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597846
[TBL] [Abstract][Full Text] [Related]
3. Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S; Onishi A; Hattori S; Dubreuil M; Ueda Y; Nishimura K; Okano T; Yamada H; Yamamoto W; Murata K; Onizawa H; Ebina K; Maeda Y; Son Y; Amuro H; Hara R; Hata K; Shiba H; Katayama M; Watanabe R; Hashimoto M; Saegusa J
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38317442
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J
Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490
[TBL] [Abstract][Full Text] [Related]
5. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study.
Martinez-Molina C; Gich I; Diaz-Torné C; Park HS; Feliu A; Vidal S; Corominas H
Sci Rep; 2024 Jan; 14(1):172. PubMed ID: 38168532
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Lauper K; Iudici M; Mongin D; Bergstra SA; Choquette D; Codreanu C; Cordtz R; De Cock D; Dreyer L; Elkayam O; Hauge EM; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Kristianslund EK; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Strangfeld A; Verschueren P; Courvoisier DS; Finckh A
Ann Rheum Dis; 2022 Oct; 81(10):1358-1366. PubMed ID: 35705376
[TBL] [Abstract][Full Text] [Related]
7. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.
Nakayama Y; Watanabe R; Yamamoto W; Ebina K; Hirano T; Kotani T; Shiba H; Katayama M; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Murakami K; Murata K; Ito H; Tanaka M; Matsuda S; Morinobu A; Hashimoto M
Rheumatology (Oxford); 2024 Feb; 63(2):349-357. PubMed ID: 37354495
[TBL] [Abstract][Full Text] [Related]
8. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.
Nakayama Y; Hashimoto M; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A
Scand J Rheumatol; 2022 Nov; 51(6):431-440. PubMed ID: 34511031
[TBL] [Abstract][Full Text] [Related]
9. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
[TBL] [Abstract][Full Text] [Related]
10. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
11. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry.
Manfredi A; Fornaro M; Bazzani C; Perniola S; Cauli A; Rai A; Favalli EG; Bugatti S; Rossini M; Foti R; Conti F; Lopalco G; Scalvini A; Garufi C; Congia M; Gorla R; Gremese E; Atzeni F; Caporali R; Iannone F; Sebastiani M
Front Med (Lausanne); 2024; 11():1349533. PubMed ID: 38529117
[TBL] [Abstract][Full Text] [Related]
12. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
14. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis.
Cho SK; Sung YK; Kim D; Won S; Choi CB; Kim TH; Jun JB; Yoo DH; Bae SC
BMC Musculoskelet Disord; 2016 Aug; 17():333. PubMed ID: 27507033
[TBL] [Abstract][Full Text] [Related]
15. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.
Cutolo M; Soldano S; Montagna P; Sulli A; Seriolo B; Villaggio B; Triolo P; Clerico P; Felli L; Brizzolara R
Arthritis Res Ther; 2009; 11(6):R176. PubMed ID: 19930661
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
[TBL] [Abstract][Full Text] [Related]
18. Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan.
Kondo M; Yamada H
Mod Rheumatol; 2019 Nov; 29(6):928-935. PubMed ID: 30334661
[No Abstract] [Full Text] [Related]
19. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
20. Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.
Desai RJ; Varma VR; Gerhard T; Segal J; Mahesri M; Chin K; Horton DB; Kim SC; Schneeweiss S; Thambisetty M
JAMA Netw Open; 2022 Apr; 5(4):e226567. PubMed ID: 35394510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
